/PCRX
PCRX Stock - Pacira BioSciences, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$21.60-5.80%
$1.33 (-5.80%) • Jan 13
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.18
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+25.0%upside
Target: $27.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PCRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.38 – $21.82
TARGET (TP)$27.00
STOP LOSS$19.87
RISK/REWARD1:3.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.23
52W High$27.64
52W Low$19.84
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $700.97M | $674.98M | $666.82M | $541.53M | $429.65M |
| Gross Profit | $530.54M | $490.31M | $467.53M | $401.28M | $312.32M |
| Gross Margin | 75.7% | 72.6% | 70.1% | 74.1% | 72.7% |
| Operating Income | $-73,371,000 | $87.67M | $60.02M | $89.92M | $46.35M |
| Net Income | $-99,560,000 | $41.95M | $15.91M | $41.98M | $145.52M |
| Net Margin | -14.2% | 6.2% | 2.4% | 7.8% | 33.9% |
| EPS | $-2.15 | $0.91 | $0.35 | $0.95 | $3.41 |
Company Overview
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PCRXBeat Rate
50%
Last 18 quarters
Avg Surprise
-0.2%
EPS vs Estimate
Beats / Misses
9/7
2 met exactly
Latest EPS
$0.70
Q4 2025
EPS Surprise History
Q1 24
0.0%
$0.89vs$0.89
Q2 24
-3.1%
$0.62vs$0.64
Q3 24
+21.9%
$0.89vs$0.73
Q4 24
+9.7%
$0.79vs$0.72
Q1 25
+16.7%
$0.91vs$0.78
Q2 25
+8.8%
$0.62vs$0.57
Q3 25
+2.8%
$0.74vs$0.72
Q4 25
+7.7%
$0.70vs$0.65
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.83 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.65 | $0.70 | +7.7% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.72 | $0.74 | +2.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.57 | $0.62 | +8.8% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $0.78 | $0.91 | +16.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.72 | $0.79 | +9.7% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $0.73 | $0.89 | +21.9% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.64 | $0.62 | -3.1% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $0.89 | $0.89 | 0.0% | = MET |
Q4 2023 | Nov 2, 2023 | $0.84 | $0.72 | -14.3% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $0.81 | $0.78 | -3.7% | ✗ MISS |
Q2 2023 | May 3, 2023 | $0.60 | $0.53 | -11.7% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $0.80 | $0.80 | 0.0% | = MET |
Q4 2022 | Nov 3, 2022 | $0.73 | $0.64 | -12.3% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $0.85 | $0.51 | -40.0% | ✗ MISS |
Q2 2022 | May 4, 2022 | $0.74 | $0.64 | -13.5% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $0.83 | $0.97 | +16.9% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.66 | $0.72 | +9.1% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $0.76 | $0.77 | +1.3% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about PCRX
What is PCRX's current stock price?
Pacira BioSciences, Inc. (PCRX) is currently trading at $21.60 per share. The stock has moved -5.80% today.
What is the analyst price target for PCRX?
The average analyst price target for PCRX is $27.00, based on 1 analyst.
What sector is Pacira BioSciences, Inc. in?
Pacira BioSciences, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is PCRX's market cap?
Pacira BioSciences, Inc. has a market capitalization of $0.98 billion, making it a small-cap company.
Does PCRX pay dividends?
No, Pacira BioSciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$48.13
Mkt Cap: $1.3B
BBOT
BridgeBio Oncology Therapeutics Inc.
$11.51
Mkt Cap: $0.9B
CRON
Cronos Group Inc.
$2.70
Mkt Cap: $1.0B
KOD
Kodiak Sciences Inc.
$28.32
Mkt Cap: $1.5B
MNMD
Mind Medicine (MindMed) Inc.
$14.87
Mkt Cap: $1.1B
OCS
Oculis Holding AG
$23.04
Mkt Cap: $1.2B
PHAT
Phathom Pharmaceuticals, Inc.
$15.63
Mkt Cap: $1.1B
TNDM
Tandem Diabetes Care, Inc.
$20.90
Mkt Cap: $1.4B
URGN
UroGen Pharma Ltd.
$19.83
Mkt Cap: $0.9B
XNCR
Xencor, Inc.
$13.94
Mkt Cap: $1.0B
Explore stocks similar to PCRX for comparison